Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilobradine high dose 1
Drug: Placebo
Drug: Cilobradine low dose 1
Drug: Cilobradine high dose 2
Drug: Cilobradine low dose 2
Drug: Cilobradine medium dose
Drug: Metoprolol succinate tablets

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 119

Registration Number: NCT02264002

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tamsulosin HCl
Drug: Ketoconazole

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02264171

Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lefradafiban
Drug: Clopidogrel

First Posted Date: 2014-10-15

Last Posted Date: 2014-10-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02265289

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: telmisartan
Drug: ASA/ER-DP

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262793

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Pramipexole Placebo
Drug: Pramipexole extended-release (ER) tablets
Drug: Moxifloxacin
Drug: Moxifloxacin Placebo
Drug: Pramipexole immediate-release (IR) tablets

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02262546

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan /HCTZ - compression tablet (DC)
Drug: Telmisartan /HCTZ - dry granulation tablet (DG)
Drug: Telmisartan /HCTZ - present commercial formulation

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02262572

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Completed

Conditions: Hypertension

Interventions: Drug: Micardis®
Drug: MicardisPlus®

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4814

Registration Number: NCT02262637

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/HCTZ fixed dose
Drug: Telmisartan
Drug: Hydrochlorthiazide (HCTZ)

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02262598

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 277 capsule
Drug: BIBR 277 tablet

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02262559

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan and HCTZ
Drug: Telmisartan
Drug: HCTZ

First Posted Date: 2014-10-13

Last Posted Date: 2014-10-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT02262858

AI-Powered Research

Premium Access

Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects

Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects

Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers

Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II